Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio.

Literature DB >> 35245101

Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio.

Jeffrey C Buchsbaum¹, Michael G Espey¹, Ceferino Obcemea¹, Jacek Capala¹, Mansoor Ahmed¹, Pataje G Prasanna¹, Bhadrasain Vikram¹, Julie A Hong¹, Beverly Teicher¹, Molykutty J Aryankalayil¹, Michelle A Bylicky¹, C Norman Coleman¹.

Abstract

Entities: Chemical

Mesh：

Year: 2022 PMID： 35245101 PMCID： PMC9177246 DOI： 10.1200/JCO.21.02579

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 50.717

Keyword Cloud
References

× No keyword cloud information.

81 in total

Review 1. Radiation oncology in the era of precision medicine.

Authors: Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal: Nat Rev Cancer Date: 2016-03-18 Impact factor: 60.716

2. Biologic Dose and Imaging Changes in Pediatric Brain Tumor Patients Receiving Spot Scanning Proton Therapy.

Authors: Kristofer W Roberts; Hok Seum Wan Chan Tseung; Laurence J Eckel; William S Harmsen; Chris Beltran; Nadia N Laack
Journal: Int J Radiat Oncol Biol Phys Date: 2019-07-10 Impact factor: 7.038

3. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.

Authors: Caroline V M Verhagen; Rosemarie de Haan; Floor Hageman; Tim P D Oostendorp; Annalisa L E Carli; Mark J O'Connor; Jos Jonkers; Marcel Verheij; Michiel W van den Brekel; Conchita Vens
Journal: Radiother Oncol Date: 2015-05-13 Impact factor: 6.280

Review 4. [RadGenomics project].

Authors: Mayumi Iwakawa; Takashi Imai; Yoshinobu Harada; Sadayuki Ban; Yu-ichi Michikawa; Kumiko Saegusa; Masasi Sagara; Atsushi Tsuji; Shuhei Noda; Atsuko Ishikawa
Journal: Nihon Igaku Hoshasen Gakkai Zasshi Date: 2002-08

5. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.

Authors: Ravi B Patel; Reinier Hernandez; Peter Carlson; Joseph Grudzinski; Amber M Bates; Justin C Jagodinsky; Amy Erbe; Ian R Marsh; Ian Arthur; Eduardo Aluicio-Sarduy; Raghava N Sriramaneni; Won Jong Jin; Christopher Massey; Alexander L Rakhmilevich; David Vail; Johnathan W Engle; Trang Le; KyungMann Kim; Bryan Bednarz; Paul M Sondel; Jamey Weichert; Zachary S Morris
Journal: Sci Transl Med Date: 2021-07-14 Impact factor: 17.956

6. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

Authors: Erik Ladomersky; Lijie Zhai; Alicia Lenzen; Kristen L Lauing; Jun Qian; Denise M Scholtens; Galina Gritsina; Xuebing Sun; Ye Liu; Fenglong Yu; Wenfeng Gong; Yong Liu; Beibei Jiang; Tristin Tang; Ricky Patel; Leonidas C Platanias; C David James; Roger Stupp; Rimas V Lukas; David C Binder; Derek A Wainwright
Journal: Clin Cancer Res Date: 2018-03-02 Impact factor: 12.531

7. ⁹⁰Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.

Authors: Reinier Hernandez; Kirsti L Walker; Joseph J Grudzinski; Eduardo Aluicio-Sarduy; Ravi Patel; Christopher D Zahm; Anatoly N Pinchuk; Christopher F Massey; Ariana N Bitton; Ryan J Brown; Paul M Sondel; Zachary S Morris; Jonathan W Engle; Christian M Capitini; Jamey P Weichert
Journal: Commun Biol Date: 2019-02-26

Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio.

Review 1. Radiation oncology in the era of precision medicine.

2. Biologic Dose and Imaging Changes in Pediatric Brain Tumor Patients Receiving Spot Scanning Proton Therapy.

3. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.

Review 4. [RadGenomics project].

5. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.

6. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

7. ⁹⁰Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.

Review 8. Can the two mechanisms of tumor cell killing by radiation be exploited for therapeutic gain?

Review 9. Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go.

10. Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care.

Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio.

Review 1. Radiation oncology in the era of precision medicine.

2. Biologic Dose and Imaging Changes in Pediatric Brain Tumor Patients Receiving Spot Scanning Proton Therapy.

3. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.

Review 4. [RadGenomics project].

5. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.

6. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

7. 90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.

Review 8. Can the two mechanisms of tumor cell killing by radiation be exploited for therapeutic gain?

Review 9. Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go.

10. Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care.

7. ⁹⁰Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.